ASK REDCHAT ANYTHING ABOUT QUINCE THERAPEUTICS INC.
Quince Therapeutics Inc. (NASDAQ: QNCX)
Listen to this Section
$17.42
-0.1200
(
-0.68% )
0.1K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| EryDexDetailsNeurological disorder, Rare genetic disease, Ataxia Telangiectasia |
Phase 3 |
| Atuzaginstat (COR388) / Lysine gingipain inhibitorDetailsAlzheimer's disease, Neurological disorder |
Failed |
| COR588 (Lysine gingipain inhibitor)DetailsMental health, Alzheimer's disease, Neurological disorder |
Failed |
| Atuzaginstat (COR388) (Lysine gingipain inhibitor)DetailsPeriodontal disease |
Failed |
| Atuzaginstat (COR388) / Lysine gingipain inhibitorDetailsParkinson's disease |
Failed |
| EryDexDetailsRare genetic disease, Neurological disorder, Ataxia Telangiectasia |
Phase 3 |
Market Data
|
| Open |
$17.42 |
| Previous Close |
$17.54 |
| Volume |
0.1K |
| Market Cap |
$17.15M |
| Day Range |
$17.41 - $17.41 |
| 52 Week Range |
$15.10 - $909.98 |
| Shares Outstanding |
0.98M |
| Change % |
-0.68% |
| Net Change |
▼ -0.1200 |
| Insider Ownership |
0.00% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| IPO Year | 2019 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-3,036,575.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-06-05 |
Sale |
-56061.00 |
Hannah Brendan |
| 2024-02-15 |
Sale |
-54000.00 |
Patni Rajiv |
| 2024-02-02 |
Sale |
-145000.00 |
Ryan Charles S. |
| 2024-02-02 |
Sale |
-600000.00 |
Hannah Brendan |
| 2024-02-02 |
Sale |
-1500000.00 |
Thye Dirk |
| 2024-01-17 |
Sale |
-90531.00 |
Thye Dirk |
| 2023-12-14 |
Buy |
300.00 |
Lamond David |
| 2023-12-07 |
Buy |
19123.00 |
Lamond David |
| 2023-12-01 |
Buy |
14378.00 |
Lamond David |
| 2023-10-26 |
Sale |
-75000.00 |
Hannah Brendan |